AMWLAmerican Well Corporation
The schedule
- Tue20Oct
Scheduled commercial rollout of AMWL's new generative AI scribe tools and enhanced virtual workflow integrations aimed at reducing provider burnout and increasing Converge platform utilization.
- Thu4Feb
Q3 print and the crucial preliminary commentary on FY2027 enterprise contracting demand, providing the first clear look at post-Converge-migration baseline growth.
- Fri12Feb
Full-year 2026 earnings delivery and potential updates on strategic alternatives or share repurchases, given the persistent disconnect between the company's cash reserves and market capitalization.
- Tue4May
- Fri7May
Past
- Wed5Aug
Actual outcome: Bull · $11.49 at outcome
AMWL beat EPS estimates of -$0.60 by -$0.06, narrowing its adjusted EBITDA loss and raising full-year profitability guidance to achieve operating and cash-flow breakeven by Q4. The stock surged on news of the DHA's intent to make Amwell a prime contractor, signaling strong validation of its platform and boosting confidence in its long-term growth prospects despite revenue declines.
AMWL will report Q2 results with investors highly focused on the company's ability to maintain its dramatically improved cash burn trajectory (net loss improved to -$10.8M last quarter) against shrinking top-line revenues.
- Wed15Jul
Actual outcome: Bull · $10.75 at outcome
American Well shares surged ahead of the CMS 2027 Physician Fee Schedule Proposed Rule, soaring 11.1% on heavy trading volume just prior to the event. This strong momentum drove the stock well above the $9.50 bull target to close at $10.95, reflecting market optimism around telehealth reimbursement rates despite cautious near-term earnings estimate revisions.
The Centers for Medicare & Medicaid Services (CMS) is expected to release the proposed 2027 Physician Fee Schedule, detailing telehealth reimbursement rates and regulatory extensions under the Trump administration.
- Tue5May
Actual outcome: Bull · $8.48 at outcome
Amwell reported Q1 2026 results that met EPS expectations and topped revenue estimates, signaling potential stabilization amid its Converge platform transition. The better-than-expected top-line performance and subsequent analyst upgrades sparked strong momentum, driving the stock up over 33% to easily exceed the bull target.
AMWL reports Q1 results with a focus on whether the -22.1% YoY revenue contraction is finally bottoming out as clients migrate to the Converge platform.
